Latest Hospira Stories
- Hospira calls for continued support of extrapolation principle to help drive increased patient access to life-saving biologic medicines - LONDON, April 24, 2015 /PRNewswire/ --
DUBLIN, April 14, 2015 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/rtp6vz/global_cancer) has announced the addition of the "Global
LAKE FOREST, Ill., April 13, 2015 /PRNewswire/ -- Hospira, Inc. (NYSE: HSP), the world's leading provider of injectable drugs and
LONDON, April 8, 2015 /PRNewswire/ -- Report Details Generic Drugs - new study showing you trends, R&D progress, and predicted revenues Where is the market
LAKE FOREST, Ill., April 7, 2015 /PRNewswire/ -- Hospira, Inc.
LONDON, April 2, 2015 /PRNewswire/ -- Biosimilar drug producers - your guide to those companies' activities and prospects What does the future hold for makers of biosimilar
-- Subsequent entry biologic (SEB) medicine provides a lower-cost, high-quality, safe and effective therapy for rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis (PsA)
-- Data presented at the National Kidney Foundation (NKF) Spring Meeting; single and multiple-dose pharmacokinetic and pharmacodynamic (PK/PD) studies support biosimilar application for Epoetin Hospira
LONDON, March 26, 2015 /PRNewswire/ -- Editor Note: For more information about this release, please scroll to bottom. Investor-Edge has initiated coverage
According to a new report by iData Research, in 2014, the U.S.
- An armed gangster.